JACC Podcast – Détails, épisodes et analyse
Détails du podcast
Informations techniques et générales issues du flux RSS du podcast.

JACC Podcast
American College of Cardiology
Fréquence : 1 épisode/1j. Total Éps: 766

Classements récents
Dernières positions dans les classements Apple Podcasts et Spotify.
Apple Podcasts
🇨🇦 Canada - medicine
01/08/2025#73🇨🇦 Canada - medicine
29/07/2025#68🇺🇸 États-Unis - medicine
29/07/2025#98🇺🇸 États-Unis - medicine
28/07/2025#98🇺🇸 États-Unis - medicine
27/07/2025#95🇺🇸 États-Unis - medicine
26/07/2025#99🇺🇸 États-Unis - medicine
25/07/2025#95🇫🇷 France - medicine
21/07/2025#85🇬🇧 Grande Bretagne - medicine
20/07/2025#75🇺🇸 États-Unis - medicine
20/07/2025#98
Spotify
Aucun classement récent disponible
Liens partagés entre épisodes et podcasts
Liens présents dans les descriptions d'épisodes et autres podcasts les utilisant également.
See allQualité et score du flux RSS
Évaluation technique de la qualité et de la structure du flux RSS.
See allScore global : 38%
Historique des publications
Répartition mensuelle des publications d'épisodes au fil des années.
Serial Shock Severity Assessment: Some Answers. Still Many Questions. | ESC 2024
samedi 31 août 2024 • Durée 11:36
Rasha K. Al-Lamee, MD, PhD, JACC Deputy Editor and Navin K. Kapur MD discuss the work from the Cardiogenic Shock Working Group, which is an academic research consortium comprising ~40 hospitals in the U.S. and internationally.
Insights from RESHAPE-HF2 Trial | ESC 2024
samedi 31 août 2024 • Durée 13:30
Aakriti Gupta, MD, FACC, JACC Executive Associate Editor, and Stefan D. Anker, MD, discuss the insights from the RESHAPE-HF2 trial - an eight-year study on the efficacy of transcatheter edge-to-edge repair for mitral valve regurgitation in patients with heart failure.
Comparative Effectiveness of Second-line Antihyperglycemic Agents for Cardiovascular Outcomes: A Multinational, Federated Analysis of LEGEND-T2DM
lundi 26 août 2024 • Durée 11:19
In the September 3, 2024, JACC issue, a major study evaluates the cardiovascular outcomes of second-line antihyperglycemic agents in type 2 diabetes, comparing SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas. The research reveals that SGLT2 inhibitors and GLP-1 receptor agonists offer superior cardiovascular protection over the other agents, highlighting their importance for patients with cardiovascular conditions.
JACC - May 28, 2024 Issue Summary
lundi 20 mai 2024 • Durée 25:46
Audio Summary of the May 28 issue of JACC, by Dr. Valentin Fuster
Safety and Efficacy of Metabolic Modulation with Ninerafaxstat in Nonobstructive Hypertrophic Cardiomyopathy: Phase 2 Study
lundi 20 mai 2024 • Durée 13:02
Commentary by Dr. Valentin Fuster
Clinical Outcome of Different Microvascular Injury Patterns after STEMI - A Multicenter Cardiac MRI Study
lundi 20 mai 2024 • Durée 13:41
Commentary by Dr. Valentin Fuster
Prognostic Value of MRR After Primary PCI: a Pooled Analysis of Individual Patient Data
lundi 20 mai 2024 • Durée 10:49
Commentary by Dr. Valentin Fuster
A Technology-Assisted Web Application for Consumer Access to a Non-prescription Statin Medication
lundi 20 mai 2024 • Durée 08:18
Commentary by Dr. Valentin Fuster
Personalized Intervention Based on Early Detection of Atherosclerosis: JACC State-of-the-Art Review
lundi 20 mai 2024 • Durée 21:51
Commentary by Dr. Valentin Fuster
Clinical Risk Assessment Across the Lifespan in Patients with Congenital Heart Disease: JACC Scientific Statement
lundi 20 mai 2024 • Durée 06:42
Commentary by Dr. Valentin Fuster